Nexus Pharmaceuticals Launches Baclofen Injection Refill Kit
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- Nexus Pharmaceuticals, LLC announces the launch of their Baclofen Injection Refill Kit. Nexus’ kit will be the only one on the market that offers a vial presentation.
“We are proud to be supplying healthcare systems with not only a life-changing drug, such as Baclofen, but also with a convenience kit to deliver the medication in a safe, accommodating, and timely fashion,” says Omair Ahmed, Chief Operating Officer at Nexus. “This kit will ease the lives of those living with long-term severe spasticity conditions.”
Baclofen Injection Refill Kits are available now. Order through your Wholesaler today or from Customer Service at (888) 806-4606.
Unit of Sale NDC: 14789-0161-01
- Cencora – 10298638
- Cardinal – 5981196
- McKesson – 3025269
- Morris & Dickson – 596312
About Nexus Pharmaceuticals, LLC: Nexus Pharmaceuticals, LLC., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality drug products fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they’re needed most.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250410021009/en/
Grace Conroy
[email protected]
847-527-7490
Source: Nexus Pharmaceuticals, LLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cyviz: Microsoft’s Immersive Approach to Collaboration
- 1B+ Coins Bought Back and Built-In Arbitrage Play: Why BlockDAG Looks Like A Smarter Choice Than XRP & ONDO Today!
- AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Resu
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share